[ad_1]
Customers with a prescription of Eli Lilly’s weight reduction drug, Zepbound, will now be capable of get the treatment delivered straight to their properties by way of Amazon.
Eli Lilly has chosen Amazon Pharmacy as a third-party supply possibility for its direct-to-consumer service LillyDirect, which launched earlier this 12 months.
“To assist sufferers being handled for diabetes, weight problems, and migraine, Amazon Pharmacy is now providing house supply of choose drugs by way of LillyDirect,” the e-commerce large said in a blog post on Wednesday.
The drug producer launched its delivery service in January as a manner to make sure sufferers have a constant provide of its drugs, as demand for Zepbound and comparable medication comparable to Novo Nordisk’s Ozempic and Wegovy has soared.
LillyDirect connects customers with impartial healthcare suppliers on-line or in-person who can write prescriptions to Zepbound and different medication. These prescriptions are then fulfilled by third-party on-line pharmacies like Truepill and now Amazon Pharmacy. Sufferers who have already got a physician can have their prescriptions fulfilled by LillyDirect, as effectively.
Skyrocketing demand for weight reduction medication
Gross sales of a brand new class of weight reduction medication generally known as GLP-1s have remodeled Eli Lilly and Novo Nordisk into the most valuable pharmaceutical companies in the world. Eli Lilly is now the world’s tenth largest firm by market capitalization, at $718 billion.
Sadly, the excessive demand has additionally made it laborious for some sufferers to have their prescriptions stuffed.
“Many sufferers report driving to 5, six, seven pharmacies to search out the medication they want,” Eli Lilly CEO David Ricks instructed traders throughout an earnings name in February. He added, that LillyDirect “simplifies the method.”
Eli Lilly rival Novo Nordisk, maker of Ozempic and Wegovy, has additionally confronted issue assembly demand. Since Could 2023, Novo Nordisk has been limiting starter doses of Wegovy to make sure there’s sufficient provide for sufferers already on the drug.
Novo Nordisk CEO Lars Fruergaard Jørgensen instructed CNBC this month that the hole between demand for weight reduction medication and the provision is overwhelming.
“It’ll take fairly some years earlier than the trade has scaled up provides to have the ability to meet this very sturdy demand,” Jørgensen mentioned.
[ad_2]
Source link